Gail McIntyre

1.2k total citations
28 papers, 964 citations indexed

About

Gail McIntyre is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gail McIntyre has authored 28 papers receiving a total of 964 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Gail McIntyre's work include Pancreatic and Hepatic Oncology Research (9 papers), Phagocytosis and Immune Regulation (9 papers) and Gastrointestinal motility and disorders (6 papers). Gail McIntyre is often cited by papers focused on Pancreatic and Hepatic Oncology Research (9 papers), Phagocytosis and Immune Regulation (9 papers) and Gastrointestinal motility and disorders (6 papers). Gail McIntyre collaborates with scholars based in United States, Austria and Norway. Gail McIntyre's co-authors include Ann H. Erickson, Paul S. Covington, James M. Davenport, Leonard S. Dove, David Andrae, Anthony Lembo, Lisa Turner, Rocío López, Ron Schey and June S. Almenoff and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Gail McIntyre

25 papers receiving 942 citations

Peers

Gail McIntyre

GASTR

SURGE

PHYSI

IMMUN

Amir P. Tamiz United States

Marilyn Harding United Kingdom

J Kolínská Czechia

Rafiquel Sarker United States

Masahiro Iizuka Japan

Naoko Kaga Japan

Toshiyuki Hikita Japan

Nam Soo Joo United States

Alexey Danilkovich United States

Silvia Galván-Peña United States

Amir P. Tamiz United States

Gail McIntyre

374 ×1.0

GASTR

425 ×1.4

245 ×1.2

SURGE

41 ×0.3

PHYSI

73 ×0.6

IMMUN

Citations per year, relative to Gail McIntyre Gail McIntyre (= 1×) peers Amir P. Tamiz

Countries citing papers authored by Gail McIntyre

Since Specialization

Citations

This map shows the geographic impact of Gail McIntyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail McIntyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail McIntyre more than expected).

Fields of papers citing papers by Gail McIntyre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail McIntyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail McIntyre. The network helps show where Gail McIntyre may publish in the future.

Co-authorship network of co-authors of Gail McIntyre

This figure shows the co-authorship network connecting the top 25 collaborators of Gail McIntyre. A scholar is included among the top collaborators of Gail McIntyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail McIntyre. Gail McIntyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.

Staufer, Katharina, Heidemarie Huber, Rudolf Stauber, et al.. (2023). Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis. Cell Death Discovery. 9(1). 282–282. 5 indexed citations

Sahai, Vaibhav, Paul E. Oberstein, Smitha Krishnamurthi, et al.. (2023). Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology. 41(16_suppl). e16258–e16258. 3 indexed citations

Fuh, Katherine C., Michael A. Bookman, Joyce F. Liu, et al.. (2021). Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic Oncology. 163(2). 254–261. 26 indexed citations

Fuh, Katherine C., Michael A. Bookman, Robert E. Coleman, et al.. (2021). Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma. Gynecologic Oncology. 162. S4–S5. 2 indexed citations

Fuh, Katherine C., Michael A. Bookman, Robert L. Coleman, et al.. (2021). Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.. Journal of Clinical Oncology. 39(15_suppl). 5566–5566.

Lembo, Anthony, Brian E. Lacy, Marc J. Zuckerman, et al.. (2016). Eluxadoline for Irritable Bowel Syndrome with Diarrhea. New England Journal of Medicine. 374(3). 242–253. 228 indexed citations

Levy‐Cooperman, Naama, Gail McIntyre, Mark E. McDonnell, et al.. (2016). Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 359(3). 471–481. 24 indexed citations

Fujita, Wakako, et al.. (2014). Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochemical Pharmacology. 92(3). 448–456. 64 indexed citations

10.

Lembo, Anthony, David Andrae, James M. Davenport, et al.. (2014). 929d Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Randomized, Double-blind, Placebo-Controlled Phase 3 Clinical Trials of Efficacy and Safety. Gastroenterology. 146(5). S–159. 9 indexed citations

11.

Dove, Leonard S., Anthony Lembo, Charles Randall, et al.. (2013). Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study. Gastroenterology. 145(2). 329–338.e1. 119 indexed citations

12.

Davenport, James M., Paul S. Covington, Mark H. Gotfried, et al.. (2012). Summary of Pharmacokinetics and Tissue Distribution of a Broad‐Spectrum Fluoroquinolone, JNJ‐Q2. Clinical Pharmacology in Drug Development. 1(4). 121–130. 11 indexed citations

13.

Biedenbach, Douglas J., et al.. (2012). Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. International Journal of Antimicrobial Agents. 39(4). 321–325. 12 indexed citations

14.

Eichenbaum, Gary, et al.. (2012). Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti‐MRSA fluoroquinolone JNJ‐Q2. British Journal of Pharmacology. 166(5). 1694–1707. 14 indexed citations

15.

Covington, Paul S., David Andrae, Charles Randall, et al.. (2012). 943e MuDelta Treatment Improves Bowel Movement Frequency and Urgency Episodes in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Results of a Phase 2 Clinical Trial. Gastroenterology. 142(5). S–161. 1 indexed citations

16.

Faqi, Ali S., et al.. (2011). Developmental Toxicity of the HMG‐CoA Reductase Inhibitor (PPD10558) in Rats and Rabbits. Birth Defects Research Part B Developmental and Reproductive Toxicology. 95(1). 23–37. 6 indexed citations

17.

Covington, Paul S., James M. Davenport, David Andrae, et al.. (2011). Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection. Antimicrobial Agents and Chemotherapy. 55(12). 5790–5797. 35 indexed citations

18.

Léonard, Renaud, Gail McIntyre, Ramón Salazar, et al.. (2001). Capecitabine named patient program for patients with advanced breast cancer: The UK experience. European Journal of Cancer. 37(15). 28–28. 14 indexed citations

19.

Lentz, Barry R., et al.. (1992). Bilayer curvature and certain amphipaths promote poly(ethylene glycol)-induced fusion of dipalmitoylphosphatidylcholine unilamellar vesicles. Biochemistry. 31(10). 2643–2653. 78 indexed citations

20.

Lambert, John M., Gail McIntyre, Vikram R. Rao, et al.. (1991). The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry. 30(13). 3234–3247. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact